Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
15/433
Matches for
“telaprevir”
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
…approved protease inhibitors (boceprevir and telaprevir), including those who have previously failed…
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
…1208 patients treated with a telaprevir-based regimen were included in the…
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
…women) with the addition of telaprevir. For genotypes 2 and 3, treatment…
-
Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?
It is estimated that hepatitis C virus (HCV) infects chronically about 160…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.
The assessment of the fibrotic evolution of chronic hepatitis has always been…
-
Ministère des Affaires Sociales et de la Santé Key publication
Showing the full result list. The page is server-rendered and not paginated.